Zura Bio Limited (NASDAQ:ZURA – Get Free Report) was the recipient of a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 3,440,000 shares, a growth of 92.2% from the July 15th total of 1,790,000 shares. Based on an average daily volume of 283,700 shares, the short-interest ratio is currently 12.1 days. Approximately 10.4% of the company’s stock are short sold.
Analyst Ratings Changes
A number of research analysts recently issued reports on ZURA shares. Oppenheimer lifted their target price on Zura Bio from $16.00 to $21.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. Piper Sandler started coverage on Zura Bio in a report on Friday, May 3rd. They issued an “overweight” rating and a $26.00 target price for the company. Finally, Cantor Fitzgerald assumed coverage on Zura Bio in a report on Wednesday, June 12th. They issued an “overweight” rating on the stock. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $19.75.
View Our Latest Analysis on ZURA
Insider Activity at Zura Bio
Institutional Investors Weigh In On Zura Bio
Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC grew its position in Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,900 shares during the last quarter. Forefront Analytics LLC raised its holdings in shares of Zura Bio by 46.8% in the fourth quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock valued at $99,000 after buying an additional 6,765 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Zura Bio by 15.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock worth $165,000 after buying an additional 6,412 shares in the last quarter. Affinity Asset Advisors LLC acquired a new stake in Zura Bio in the 1st quarter valued at about $1,157,000. Finally, Armistice Capital LLC raised its stake in shares of Zura Bio by 15.4% in the fourth quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock worth $8,518,000 after acquiring an additional 244,000 shares during the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.
Zura Bio Trading Down 2.4 %
ZURA stock opened at $3.29 on Wednesday. Zura Bio has a 1-year low of $2.00 and a 1-year high of $7.63. The business’s 50 day moving average is $3.65 and its 200-day moving average is $3.76.
Zura Bio Company Profile
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Featured Stories
- Five stocks we like better than Zura Bio
- How to Use Stock Screeners to Find Stocks
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- What Are Dividends? Buy the Best Dividend Stocks
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Where Do I Find 52-Week Highs and Lows?
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.